<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048711</url>
  </required_header>
  <id_info>
    <org_study_id>ASB-01-04</org_study_id>
    <nct_id>NCT00048711</nct_id>
  </id_info>
  <brief_title>Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI</brief_title>
  <official_title>Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The purpose of the study is evaluate the efficacy, safety, and pharmacokinetics of weekly&#xD;
      intravenous infusions of 1 mg/kg recombinant human N-acetylgalactosamine 4-sulfatase (rhASB)&#xD;
      in patients diagnosed with Mucopolysaccharidosis VI (MPS VI)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-minute walk test</measure>
    <time_frame>weeks 6, 12, 24, 48, 96 and 144</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>urinary glycoaminoglycan(uGAG)levels</measure>
    <time_frame>weeks 1, 4, 6, 8, 12</time_frame>
  </primary_outcome>
  <condition>Mucopolysaccharidosis VI</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylgalactosamine 4-sulfatase</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient consent&#xD;
&#xD;
          -  Patient must be five years of age or older&#xD;
&#xD;
          -  Patient must have documented biochemical or genetic proof of MPS VI&#xD;
&#xD;
          -  Patient must walk at least 1 meter, but less than 250 meters, in the first 6 minutes&#xD;
             of the baseline 12-minute walk test&#xD;
&#xD;
          -  If female of childbearing potential, patient must have a negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is under consideration for or has undergone a successful bone marrow&#xD;
             transplant (BMT).&#xD;
&#xD;
          -  Pregnant or lactating patient&#xD;
&#xD;
          -  Patient has received an investigational drug within 30 days prior to study enrollment&#xD;
&#xD;
          -  Patient has been previously treated with rhASB&#xD;
&#xD;
          -  Patient has a medical condition, serious intercurrent illness, or other extenuating&#xD;
             circumstance that may significantly confound study results or decrease study&#xD;
             compliance&#xD;
&#xD;
          -  Patient has a known hypersensitivity to rhASB or to components of the study drug&#xD;
&#xD;
          -  History of cancer (except low grade and fully resolved skin malignancy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart J Sweidler, MD, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioMarin Pharmaceutical Inc.</name>
      <address>
        <city>Novato</city>
        <state>California</state>
        <zip>94949</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmrn.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>November 6, 2002</study_first_submitted>
  <study_first_submitted_qc>November 7, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2002</study_first_posted>
  <last_update_submitted>August 24, 2009</last_update_submitted>
  <last_update_submitted_qc>August 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

